Literature DB >> 11716205

Inflammation and structural changes in the airways of patients with primary Sjögren's syndrome.

K Amin1, D Lúdvíksdóttir, C Janson, O Nettelbladt, B Gudbjörnsson, S Valtysdóttir, E Björnsson, G M Roomans, G Boman, L Sevéus, P Venge.   

Abstract

The present study aimed to compare the cellular pattern and structural changes in the airways of patients with primary Sjögren's syndrome (pSS) with healthy controls. Bronchial biopsy specimens were obtained from seven subjects with pSS and seven healthy controls. All the patients with pSS had increased bronchial responsiveness to methacholine. In the biopsies inflammatory cells, cytokine-producing cells, tenascin and laminin were visual zed by immunostaining. Patients with pSS had a higher number of neutrophils and mast cells than healthy controls, while the number of eosinophils was similar in the two groups. The number of IL-8-positive cells was higher in pSS butthe numbers of IL-4-and IL-5-positive cells were not significantly different between pSS and healthy controls. The numbers of T cells in patients with pSS were higher than in healthy controls, while the numbers of CD25-positive cells were similar to the healthy controls. The degree of epithelial integrity in patients with pSS was significantly lower than in the control group and the tenascin and laminin layers were significantly thicker in the pSS group. There was a correlation between the number of mast cells and the thickness of the tenascin and laminin layers in pSS. In conclusion, we found that the cellular pattern in the bronchial mucosa of patients with pSS displayed large numbers of neutrophils, mast cells and T-lymphocytes. These changes in inflammatory cell numbers seemed to relate to the observed increased epithelial damage and structural changes of the subepithelium. The structural findings, but not the pattern of inflammatory cells, are shared with atopic asthma and may relate to the increased bronchial hyper-responsiveness seen in both diseases.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11716205     DOI: 10.1053/rmed.2001.1174

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  6 in total

1.  Tenascin-C is an endogenous activator of Toll-like receptor 4 that is essential for maintaining inflammation in arthritic joint disease.

Authors:  Kim Midwood; Sandra Sacre; Anna M Piccinini; Julia Inglis; Annette Trebaul; Emma Chan; Stefan Drexler; Nidhi Sofat; Masahide Kashiwagi; Gertraud Orend; Fionula Brennan; Brian Foxwell
Journal:  Nat Med       Date:  2009-06-28       Impact factor: 53.440

2.  Salivary chemokine levels in patients with primary Sjogren's syndrome.

Authors:  Yun Jong Lee; Robert H Scofield; Joon Young Hyon; Pil-Young Yun; Hyo-Jung Lee; Eun Young Lee; Eun Bong Lee; Yeong Wook Song
Journal:  Rheumatology (Oxford)       Date:  2010-06-04       Impact factor: 7.580

3.  Tenascin-C produced by oxidized LDL-stimulated macrophages increases foam cell formation through Toll-like receptor-4.

Authors:  Rui Liu; Yong He; Bo Li; Jun Liu; Yingang Ren; Wei Han; Xing Wang; Lihua Zhang
Journal:  Mol Cells       Date:  2012-06-12       Impact factor: 5.034

4.  Risk of asthma in patients with primary Sjögren's syndrome: a retrospective cohort study.

Authors:  Te-Chun Shen; Hsuan-Ju Chen; Chang-Ching Wei; Chia-Hung Chen; Chih-Yen Tu; Te-Chun Hsia; Chuen-Ming Shih; Wu-Huei Hsu; Fung-Chang Sung; Da-Tian Bau
Journal:  BMC Pulm Med       Date:  2016-11-16       Impact factor: 3.317

5.  Respiratory symptoms are poor predictors of concomitant chronic obstructive pulmonary disease in patients with primary Sjögren's syndrome.

Authors:  Victor Strevens Bolmgren; Peter Olsson; Per Wollmer; Roger Hesselstrand; Thomas Mandl
Journal:  Rheumatol Int       Date:  2017-02-27       Impact factor: 2.631

6.  Sensitization to pets is a major determinant of persistent asthma and new asthma onset in Sweden.

Authors:  Monica Uddenfeldt; Christer Janson; Erik Lampa; Anna Rask-Andersen
Journal:  Ups J Med Sci       Date:  2013-01-22       Impact factor: 2.384

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.